ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Boehringer, Mirati Therapeutics Enter Clinical Collaboration
September 18, 2020To evaluate the combination of BI 1701963, a SOS1::pan-KRAS inhibitor, and MRTX849, a KRAS G12C selective inhibitor in patients with solid tumors. -
Strata Oncology, Mirati Announce Partnership for MRTX849 Trial
August 18, 2020Strata Oncology has signed an agreement with Mirati Therapeutics to broaden patient identification and enrollment for Mirati's Phase 1/2 study of MRTX849 in patients with cancer having a KRAS G12C mutation. -
Mirati Announces Clearance of IND Application for MRTX849 Trial
December 03, 2018Mirati Therapeutics announced the U.S. Food and Drug Administration (FDA) has cleared the company's investigational new drug (IND) application for .....
Pharma Sources Insight January 2025
